129 related articles for article (PubMed ID: 37960879)
21. The incidence and management of infusion reactions to infliximab: a large center experience.
Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
[TBL] [Abstract][Full Text] [Related]
22. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
23. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
24. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M
Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521
[TBL] [Abstract][Full Text] [Related]
25. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Argiris A; Seropian S; Cooper DL
Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
27. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
28. Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature.
Pringle NR; Gilbar PJ; Grewal GD
J Oncol Pharm Pract; 2022 Jun; 28(4):1019-1023. PubMed ID: 35037804
[TBL] [Abstract][Full Text] [Related]
29. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A
Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200
[TBL] [Abstract][Full Text] [Related]
30. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
31. Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.
Ahmed T; Cook P; Feldman E; Coombe N; Puccio C; Mittelman A; Chun H; Coleman M; Helson L
Leukemia; 1994 Apr; 8(4):531-4. PubMed ID: 8152247
[TBL] [Abstract][Full Text] [Related]
32. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
[TBL] [Abstract][Full Text] [Related]
33. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
Castellino SM; Pei Q; Parsons SK; Hodgson D; McCarten K; Horton T; Cho S; Wu Y; Punnett A; Dave H; Henderson TO; Hoppe BS; Charpentier AM; Keller FG; Kelly KM
N Engl J Med; 2022 Nov; 387(18):1649-1660. PubMed ID: 36322844
[TBL] [Abstract][Full Text] [Related]
35. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
36. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
[TBL] [Abstract][Full Text] [Related]
37. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
38. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
39. High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 2000 Feb; 85(2):217-9. PubMed ID: 10681738
[No Abstract] [Full Text] [Related]
40. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]